These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
672 related articles for article (PubMed ID: 17626713)
1. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Farsang C; Athyros V; Gaw A; Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019 [TBL] [Abstract][Full Text] [Related]
3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
4. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Martineau P; Gaw A; de Teresa E; Farsang C; Gensini GF; Leiter LA; Langer A; Atherosclerosis; 2007 Mar; 191(1):135-46. PubMed ID: 16643923 [TBL] [Abstract][Full Text] [Related]
5. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
6. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A; J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192 [TBL] [Abstract][Full Text] [Related]
7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
8. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Gensini GF; Gori AM; Dilaghi B; Rostagno C; Gaw A; Blanco-Colio LM; de Teresa E; Egido J; Farsang C; Leiter LA; Martineau P; Nozza A; Langer A; Int J Cardiol; 2010 Jul; 142(3):257-64. PubMed ID: 19217176 [TBL] [Abstract][Full Text] [Related]
9. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW; Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326 [TBL] [Abstract][Full Text] [Related]
11. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). McPherson R; Angus C; Murray P; Genest J; Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077 [TBL] [Abstract][Full Text] [Related]
14. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J; Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW; Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438 [TBL] [Abstract][Full Text] [Related]
17. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB; Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446 [TBL] [Abstract][Full Text] [Related]
18. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M; Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Jones PH; McKenney JM; Karalis DG; Downey J Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Leibovitz E; Harats D; Gavish D Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]